Education
About Us
Working with TipRanks
Follow Us
Acurx Pharmaceuticals (ACXP)
NASDAQ:ACXP
Earnings Data
Report Date
Mar 12, 2026After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-1.01Last Year’s EPS
-3.2Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive developments, such as achieving NASDAQ compliance, patent expansion, and successful presentations, alongside ongoing financial challenges and significant reductions in R&D expenses. The company's improved financial position and strategic scientific advancements were notable, though the net loss and reduced R&D spending highlight areas of concern.Company Guidance
NASDAQ Compliance Achieved
Acurx Pharmaceuticals effected a 1-for-20 reverse stock split, regaining compliance with NASDAQ listing rules with a minimum bid price of $1 per share and a stockholder equity threshold of $2.5 million.
Patent Expansion
The Australian Patent Office granted a new patent for DNA polymerase 3C inhibitors, adding to existing patents in the U.S., Israel, Japan, and India, strengthening intellectual property for ACX-375C program.
Successful Presentation at ID Week
Acurx was selected to present at ID Week in Atlanta, showcasing ibezapolstat's microbiome-sparing properties and new colonic microbiome data, indicating a low probability of increasing risk for certain infections.
Publication in Nature Communications
Results from a collaboration with Leiden University Medical Center were published, revealing structural biology research on ibezapolstat, marking an important milestone in scientific collaboration.
Financial Position Improvement
The company ended the quarter with $5.9 million in cash, compared to $3.7 million at the end of 2024, and raised additional funds from warrant exercises and equity line of credit.
ACXP Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ACXP Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 12, 2025 | $5.58 | $4.98 | -10.75% |
Aug 12, 2025 | $4.48 | $4.44 | -0.89% |
May 13, 2025 | $7.91 | $7.60 | -3.92% |
Mar 18, 2025 | $9.46 | $8.12 | -14.16% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Acurx Pharmaceuticals (ACXP) report earnings?
Acurx Pharmaceuticals (ACXP) is schdueled to report earning on Mar 12, 2026, After Close (Confirmed).
What is Acurx Pharmaceuticals (ACXP) earnings time?
Acurx Pharmaceuticals (ACXP) earnings time is at Mar 12, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ACXP EPS forecast?
ACXP EPS forecast for the fiscal quarter 2025 (Q4) is -1.01.